Front. Cell. Infect. Microbiol. Frontiers in Cellular and Infection Microbiology Front. Cell. Infect. Microbiol. 2235-2988 Frontiers Media S.A. 10.3389/fcimb.2026.1797134 Correction Correction: Tripterygium glycosides sensitizes cisplatin chemotherapeutic potency by modulating gut microbiota in epithelial ovarian cancer ZhanXinlu 1 † ‡ Writing – original draft Writing – review & editing Data curation Formal analysis Investigation Methodology Validation ZuoQi 2 † Writing – original draft Formal analysis Methodology HuangGenhua 1 Writing – original draft QiZhanghua 3 Writing – original draft WangYufan 3 ZhuSihong 1 Writing – original draft ZhongYanying 1 Writing – original draft XiongYifei 1 Writing – original draft ChenTingtao 3 * ‡ Writing – review & editing Writing – original draft Investigation Supervision TanBuzhen 1 * Writing – review & editing Writing – original draft Investigation Supervision Department of Obstetrics & Gynecology, The Second Affiliated Hospital of Nanchang University, Nanchang, China Department of Obstetrics & Gynecology, Ji’an Central People’s Hospital, Ji’an, China Institute of Translational Medicine, Nanchang University, Nanchang, China Correspondence: Tingtao Chen, chentingtao1984@163.com; Buzhen Tan, tanbuzhen@sina.com

These authors have contributed equally to this work and share first authorship

ORCID: Xinlu Zhan, orcid.org/0000-0002-5518-7752; Tingtao Chen, orcid.org/0000-0002-0506-8536

 25 02 2026 2026 16 1797134 27 01 2026 30 01 2026 Copyright © 2026 Zhan, Zuo, Huang, Qi, Wang, Zhu, Zhong, Xiong, Chen and Tan. 2026 Zhan, Zuo, Huang, Qi, Wang, Zhu, Zhong, Xiong, Chen and Tan https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. A Correction on Tripterygium glycosides sensitizes cisplatin chemotherapeutic potency by modulating gut microbiota in epithelial ovarian cancer By Zhan X, Zuo Q, Huang G, Qi Z, Wang Y, Zhu S, Zhong Y, Xiong Y, Chen T and Tan B (2023) Front. Cell. Infect. Microbiol. 13:1236272. doi: 10.3389/fcimb.2023.1236272 GTW gut microbiota chemosensitization Lactobacillus acidophilus intestinal barrier section-at-acceptance Intestinal Microbiome

There was a mistake in Figure 1 and Figure 3 as published. In Figure 1G, 3G, some images contain duplicated areas. Specifically, these occur between: Figure 1G (representative immunohistochemical expression of P-STAT3 in tumor tissues of the MDG group) and Figure 2G (representative immunohistochemical expression of P-STAT3 in tumor tissues of the MDG group); Figure 2G (representative immunohistochemical expression of PCNA in tumor tissues of the MADG-I group) and Figure 3G (representative immunohistochemical expression of PCNA in tumor tissues of the MADG-II group). The corrected Figure 1 and Figure 3 appear below.

(A) Schematic of schedule of whole experiment. (B) CA125 and HE4 level in serum (n = 3). (C) Weights and volumes of tumours in different treatment groups. (D) Representative H&E staining image in tumour tissues (400x). Scale bsars, 50 µm. (E) Effect of different drugs on the protein expression in tumour tissues (n = 3). (F) Relative expression of IL-6, p-STAT3/STAT3 and p-p65/p65 in tumour tissues by ImageJ software (n = 3). (G) Representative immunohistochemical expression of PCNA and p-STAT3 in tumour tissues (100x). Scale bars, 200 µm. (H, I) Statistic analysis of PCNA and p-STAT3 positive cell expression in different drug groups. Five fields of three tumour sections from each group were randomly selected and examined. *p < 0.05, **p < 0.01, ***p < 0.001. NC stands for normal control group, MC stands for model control group, MD stands for model + DDP group, MG stands for model + GTW group, MDG stands for model + DDP + GTW group. ns, no significance.

Figure with multiple panels showing a mouse experiment schedule (panel A), violin and bar plots of serum markers and tumor metrics (panels B and C), histological H&E stained tumor sections (panel D), Western blots for IL-6, STAT3, p65, and GAPDH (panel E), quantifications of protein levels and ratios (panel F), immunohistochemistry images for PCNA and p-STAT3 (panel G), and corresponding quantifications as scatter plots (panels H and I); statistical significance is indicated with asterisks throughout.

(A) Schematic of schedule of whole experiment. (B) CA125 and HE4 level in serum (n = 3). (C) Weights and volumes of tumours in different treatment groups. (D) Representative H&E staining image in tumour tissues (400x). Scale bars, 50 µm. (E) Effect of different drugs on the protein expression in tumour tissues (n = 3). (F) Relative expression of IL-6, p-STAT3/STAT3 and p-p65/p65 in tumour tissues by ImageJ software (n = 3). (G) Representative immunohistochemical expression of PCNA and p-STAT3 in tumour tissues (100x). Scale bars, 200 µm. (H, I) Statistic analysis of PCNA and p-STAT3 positive cell expression in different drug groups. Five fields of three tumour sections from each group were randomly selected and examined. *p < 0.05, **p < 0.01, ***p < 0.001. MADG-II stands for model + antibiotic +DDP + GTW group, MADG + LAP stands for model + antibiotic + GTW + DDP + L. acidophilus group, MADG + FMT stands for model + antibiotic + GTW + DDP + fecal bacteria transplantation group. ns, no significance.

Scientific figure includes a mouse model experimental timeline (A), violin and bar plots comparing serum biomarkers, tumor weight, and tumor volume across experimental groups (B, C), representative H&E-stained tumor histology images (D), Western blot results for inflammatory and signaling proteins (E), corresponding quantified bar graphs (F), immunohistochemistry images for PCNA and p-STAT3 (G), and scatter plots quantifying positive cell percentages (H, I), illustrating effects of different treatments on tumor progression and related markers.

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland